SL VaxiGen

Business Services · United States · 1-10 Employees

View Company Info for Free

Overview

Headquarters

United States

Revenue

<$5 Million

Industry

Business Services Research & Development
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1

About SL VaxiGen

SL VaxiGen is R&D company dedicated to developing innovative vaccine therapeutics based on complementary platforms for saving lives. Our goal is to save lives by various innovative genetic and protein engineering technologies especially for infectious diseases and cancers. MOGAM Institute for Biomedical Research, Vice President University of Maryland School of Medicine, Postdoc Graduate School of Medical Science and Engineering, KAIST, Professor 26th International Symposium on Hepatitis C Virus and Related Viruses, Organizer To induce antigen-specific strong and broad immunity, we combined the disease-specific multiple antigens and applied antigen engineering technologies such as codon optimization and gene shuffling in efficient expression vector system. The adaptive immunity which is mainly composed of T cell and B cell (antibody) plays an crucial role in prevention and/or treatment of diseases. Thus, increasing the specific immune response to a certain pathogen is important for theRead more
Popular SearchesSL VaxiGen IncSIC Code 87,873NAICS Code 54,541Show more

SL VaxiGen Org Chart

PhoneEmail
JS
United States flag for contact location.

Manager, Regulatory Affairs

PhoneEmail

PhoneEmail
Get the full picture
Sign in to uncover key details.

Is SL VaxiGen your ideal customer?

Let us give you the heads up on whether it's a good time to reach out

Recommended Actions

Compare Similar Companies to SL VaxiGen

Compare insights from companies similar to SL VaxiGen, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.

Company Name

Revenue

Number of Employees

Type

Funding

Founded In

Top Executive

SL VaxiGen

<$5M
1-10
Private
-
-
JS
Juah ShinManager, Regulatory Affairs
$6.5M
11-50
Public
$340.5M
2015
KB
Kristi BalacyHead Senior Director, Clinical Development Operations & of Clinical Operations
<$5M
1-10
Private
-
-
N/A
<$5M
11-50
Private
$45.6M
2016
Niranjan Sardesai, Founder, President & Chief Executive Officer at Geneos Therapeutics
Niranjan SardesaiFounder, President & CEO
<$5M
11-50
Private
-
-
N/A
<$5M
11-50
Private
$50M
2020
MK
Michael KauffmanCEO & President
<$5M
1-10
Private
-
1998
Illustration of an envelope

Company Profile Activity

i

Among all Business Services companies

Low Activity

High Activity

Activity Insights

SL VaxiGen is experiencing very low activity levels compared to other companies in the Business Services sector.

What does this means?

SL VaxiGen is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about SL VaxiGen.

SL VaxiGen Tech Stack

A closer look at the technologies used by SL VaxiGen

See more technologies

Top Business Services Companies

Frequently Asked Questions Regarding SL VaxiGen

What is SL VaxiGen's official website?
SL VaxiGen's official website is www.slvaxigen.com
What is SL VaxiGen's Revenue?
SL VaxiGen's revenue is <$5 Million
What is SL VaxiGen's SIC code?
SL VaxiGen's SIC: 87,873
What is SL VaxiGen's NAICS code?
SL VaxiGen's NAICS: 54,541
How many employees does SL VaxiGen have?
SL VaxiGen has 1-10 employees
What industry does SL VaxiGen belong to?
SL VaxiGen is in the industry of: Business Services, Research & Development
What is SL VaxiGen competition?
SL VaxiGen top competitors include: Geneos Therapeutics, Center for Viral Systems Biology, Prothix, GeneCure
What technology does SL VaxiGen use?
Some of the popular technologies that SL VaxiGen uses are: PHP, Cafe24
What does SL VaxiGen do?

SL VaxiGen is R&D company dedicated to developing innovative vaccine therapeutics based on complementary platforms for saving lives. Our goal is to save lives by various innovative genetic and protein engineering technologies especially for infectious diseases and cancers. MOGAM Institute for Biomedical Research, Vice President University of Maryla... nd School of Medicine, Postdoc Graduate School of Medical Science and Engineering, KAIST, Professor 26th International Symposium on Hepatitis C Virus and Related Viruses, Organizer To induce antigen-specific strong and broad immunity, we combined the disease-specific multiple antigens and applied antigen engineering technologies such as codon optimization and gene shuffling in efficient expression vector system. The adaptive immunity which is mainly composed of T cell and B cell (antibody) plays an crucial role in prevention and/or treatment of diseases. Thus, increasing the specific immune response to a certain pathogen is important for the development immunotherapeutic. BSA, bi-specific adaptive adjuvant, is designed for increasing antigen-specific (or vaccine-induced) adaptive immune responses by binding two or more targets in simultaneously. We have identified multiple potential mechanistic application of the BSA platform, including the three described below, - Targeting to vaccine-induced CTLs. This version of BSA molecules enable the vaccine-induced CTL (cytotoxic T lymphocyte) to be selectively increased in the course of immune responses. - Targeting to vaccine-induced GC B cells or TFH cells. This version of BSA molecules can stimulate the vaccine-induced GC B cells and/or TFH cell result in increase of vaccine-induced antibody responses. - Simultaneous targeting of multiple co-stimulatory receptors or cytokine receptors, such as those involved in T cell responses and antibody responses. Combination of multiple co-stimulatory or cytokine receptors have resulted in significantly enhanced benefit than targeting any one of the targets of them separately. BSA is ...Read More

Is SL VaxiGen a public company?
SL VaxiGen is private company therefore does not currently have an official ticker symbol
See more information about SL VaxiGen

Get Started with ZoomInfo

Register for free

Sign Up for Free

Get started for free! No credit card needed. Enjoy up to 25 free contacts each month at no cost.
Elevate your prospecting to the next level

Supercharge Your Prospecting

Search ZoomInfo's database of 106M+ companies and 140M+ professionals to find your next lead.
Expand your business

Grow Your Business

Reveal both personal and business contact details, including emails and phone numbers, and close your most valuable buyers.